Quarterly ResultJul 23, 2026, 07:01 AM
NovoCure Q2 Revenue $183.6M, Net Loss Narrows to $15.7M
AI Summary
NovoCure Ltd reported Q2 2026 net revenues of $183.6 million, a 15.6% increase year-over-year, with the net loss significantly narrowing to $15.7 million from $40.1 million in Q2 2025. For the first six months of 2026, net revenues grew to $357.6 million, though the net loss widened to $86.8 million. The company also updated its 2024 Omnibus Incentive Plan, adding 9 million ordinary shares for grant, and opted not to draw additional tranches from its senior secured credit facility.
Key Highlights
- Q2 2026 net revenues increased 15.6% to $183.6 million.
- Q2 2026 net loss narrowed to $15.7 million from $40.1 million YoY.
- Q2 2026 basic and diluted EPS improved to $(0.13) from $(0.36).
- H1 2026 net revenues grew to $357.6 million.
- H1 2026 net cash used in operating activities improved to $(5.4) million.
- 2024 Omnibus Incentive Plan amended to add 9 million ordinary shares.
- Company did not draw Tranche C or D of its $400 million credit facility.
Price Impact
More from NVCR